Manufacturer of Controlled Substances; Notice of Registration; Cayman Chemical Company, 23959-23960 [2013-09530]

Download as PDF 23959 Federal Register / Vol. 78, No. 78 / Tuesday, April 23, 2013 / Notices interest at this time. DEA has investigated S & B Pharma Inc., to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems; verification of the company’s compliance with state and local laws; and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed. Dated: April 17, 2013. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 2013–09532 Filed 4–22–13; 8:45 am] DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Registration; Alltech Associates, Inc. BILLING CODE 4410–09–P By Notice dated November 14, 2012 and published in the Federal Register on November 23, 2012, 77 FR 70188, Alltech Associates, Inc., 2051 Waukegan Road, Deerfield, Illinois 60015, made application to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following basic classes of controlled substances: Drug Schedule 2C–T–2 (2-(4-Ethylthio-2,5-dimethoxyphenyl)ethanamine) (7385) ............................................................................................................. 2C–1 (2-(4-lodo-2,5-dimethoxyphenyl)ethanamine) (7518) ........................................................................................................................ 2C–C (2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (7519) ..................................................................................................................... The company plans to manufacture high purity drug standards used for analytical applications only in clinical, toxicological, and forensic laboratories. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Alltech Associates, Inc. to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated Alltech Associates, Inc. to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with state and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR § 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed. Dated: April 16, 2013. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. mstockstill on DSK4VPTVN1PROD with NOTICES [FR Doc. 2013–09531 Filed 4–22–13; 8:45 am] BILLING CODE 4410–09–P VerDate Mar<15>2010 17:51 Apr 22, 2013 Jkt 229001 DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Registration; PCAS-Nanosyn, LLC By Notice dated January 15, 2013, and published in the Federal Register on January 30, 2013, 78 FR 6350, PCASNanosyn, LLC, 3331–B Industrial Drive, Santa Rosa, California 95403, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following basic classes of controlled substances: Drug Schedule Amphetamine (1100) .................... Methamphetamine (1105) ............ Methylphenidate (1724) ................ Phencyclidine (7471) .................... Codeine (9050) ............................. Oxycodone (9143) ........................ Hydromorphone (9150) ................ Hydrocodone (9193) ..................... Methadone (9250) ........................ Morphine (9300) ........................... Oxymorphone (9652) ................... Fentanyl (9801) ............................ II II II II II II II II II II II II The company is a contract manufacturer. At the request of the company’s customers, it manufactures derivatives of controlled substances in bulk form only. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of PCAS-Nanosyn, LLC., to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has PO 00000 Frm 00077 Fmt 4703 Sfmt 4703 I I I investigated PCAS-Nanosyn, LLC., to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with state and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR § 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed. Dated: April 16, 2013. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 2013–09529 Filed 4–22–13; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Registration; Cayman Chemical Company By Notice dated November 14, 2012, and published in the Federal Register on November 23, 2012, 77 FR 70188, Cayman Chemical Company, 1180 East Ellsworth Road, Ann Arbor, Michigan 48108, made application to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following basic classes of controlled substances: E:\FR\FM\23APN1.SGM 23APN1 23960 Federal Register / Vol. 78, No. 78 / Tuesday, April 23, 2013 / Notices Schedule Drug JWH–250 (6250) .......................... SR–18 also known as RCS–8 (7008). JWH–019 (7019) .......................... JWH–081 (7081) .......................... SR–19 also known as RCS–4 (7104). JWH–122 (7122) .......................... AM–2201 (7201) ........................... JWH–203 (7203) .......................... 2C–T–2 (7385) ............................. JWH–398 (7398) .......................... Psilocybin (7437) .......................... Psilocyn (7438) ............................. 2C–D (7508) ................................. 2C–E (7509) ................................. 2C–H (7517) ................................. 2C–I (7518) .................................. 2C–C (7519) ................................. 2C–N (7521) ................................. 2C–P (7524) ................................. 2C–T–4 (7532) ............................. AM–694 (7694) ............................. Phenylacetone (8501) .................. NUCLEAR REGULATORY COMMISSION I I [NRC–2013–0001] Sunshine Act Meetings I I I AGENCY HOLDING THE MEETINGS: Nuclear Regulatory Commission. DATES: Weeks of April 22, 29, May 6, 13, 20, 27, 2013. PLACE: Commissioners’ Conference Room, 11555 Rockville Pike, Rockville, Maryland. STATUS: Public and Closed. I I I I I I I I I I I I I I I I I Week of April 22, 2013 Monday April 22, 2013 9:00 a.m. Meeting with the Department of Energy Office of Nuclear Energy (Public Meeting) (Contact: Brett Rini, 301–251–7615). This meeting will be webcast live at the Web address—www.nrc.gov. 2:30 p.m. Discussion of Management and Personnel Issues (Closed—Ex. 2 and 6). mstockstill on DSK4VPTVN1PROD with NOTICES The company plans to manufacture the listed controlled substances for distribution to their research and forensic customers conducting drug testing and analysis. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Cayman Chemical Company to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated Cayman Chemical Company to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with state and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed. Dated: April 16, 2013. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 2013–09530 Filed 4–22–13; 8:45 am] BILLING CODE 4410–09–P VerDate Mar<15>2010 17:51 Apr 22, 2013 Jkt 229001 Tuesday April 23, 2013 9:00 a.m. Briefing on the Status of Lessons Learned from the Fukushima Dai’ichi Accident (Public Meeting) (Contact: William D. Reckley, 301–415–7490). This meeting will be webcast live at the Web address—www.nrc.gov. Week of April 29, 2013—Tentative There are no meetings scheduled for the week of April 29, 2013. Week of May 6, 2013—Tentative There are no meetings scheduled for the week of May 6, 2013. * The schedule for Commission meetings is subject to change on short notice. To verify the status of meetings, call (recording)—301–415–1292. Contact person for more information: Rochelle Bavol, 301–415–1651. * * * * * The NRC Commission Meeting Schedule can be found on the Internet at: https://www.nrc.gov/public-involve/ public-meetings/schedule.html. * * * * * The NRC provides reasonable accommodation to individuals with disabilities where appropriate. If you need a reasonable accommodation to participate in these public meetings, or need this meeting notice or the transcript or other information from the public meetings in another format (e.g., Braille, large print), please notify Kimberly Meyer, NRC Disability Program Manager, at 301–287–0727, or by email at kimberly.meyerchambers@nrc.gov. Determinations on requests for reasonable accommodation will be made on a case-by-case basis. * * * * * This notice is distributed electronically to subscribers. If you no longer wish to receive it, or would like to be added to the distribution, please contact the Office of the Secretary, Washington, DC 20555 (301–415–1969), or send an email to darlene.wright@nrc.gov. Dated: April 18, 2013. Rochelle C. Bavol, Policy Coordinator, Office of the Secretary. [FR Doc. 2013–09652 Filed 4–19–13; 4:15 pm] BILLING CODE 7590–01–P Week of May 13, 2013—Tentative There are no meetings scheduled for the week of May 13, 2013. REAGAN-UDALL FOUNDATION FOR THE FOOD AND DRUG ADMINISTRATION Week of May 20, 2013—Tentative [BAC 416404] Monday, May 20, 2013 9:30 a.m. Briefing on Human Capital and Equal Employment Opportunity (EEO) (Public Meeting) (Contact: Kristin Davis, 301–287– 0707). This meeting will be webcast live at the Web address—www.nrc.gov. Annual Public Meeting Week of May 27, 2013—Tentative Wednesday, May 29, 2013 9:00 a.m. Briefing on Results of the Agency Action Review Meeting (AARM) (Public Meeting) (Contact: Rani Franovich, 301–415–1868). This meeting will be webcast live at the Web address—www.nrc.gov. * * * * * PO 00000 Frm 00078 Fmt 4703 Sfmt 4703 ACTION: Notice of annual meeting. The Reagan-Udall Foundation for the Food and Drug Administration (FDA), which was created by Title VI of the Food and Drug Amendments of 2007, is announcing an annual open public meeting. The Foundation will provide an overview of its history, project updates, as well as projected activities going forward. DATES: The open public meeting will be held on May 23, 2013, from 10 a.m. until 12 noon. Interested persons may sign up to attend in person and/or make comments at the meeting or submit written comments by visiting https:// SUMMARY: E:\FR\FM\23APN1.SGM 23APN1

Agencies

[Federal Register Volume 78, Number 78 (Tuesday, April 23, 2013)]
[Notices]
[Pages 23959-23960]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-09530]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Registration; 
Cayman Chemical Company

    By Notice dated November 14, 2012, and published in the Federal 
Register on November 23, 2012, 77 FR 70188, Cayman Chemical Company, 
1180 East Ellsworth Road, Ann Arbor, Michigan 48108, made application 
to the Drug Enforcement Administration (DEA) to be registered as a bulk 
manufacturer of the following basic classes of controlled substances:

[[Page 23960]]



------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
JWH-250 (6250).............................  I
SR-18 also known as RCS-8 (7008)...........  I
JWH-019 (7019).............................  I
JWH-081 (7081).............................  I
SR-19 also known as RCS-4 (7104)...........  I
JWH-122 (7122).............................  I
AM-2201 (7201).............................  I
JWH-203 (7203).............................  I
2C-T-2 (7385)..............................  I
JWH-398 (7398).............................  I
Psilocybin (7437)..........................  I
Psilocyn (7438)............................  I
2C-D (7508)................................  I
2C-E (7509)................................  I
2C-H (7517)................................  I
2C-I (7518)................................  I
2C-C (7519)................................  I
2C-N (7521)................................  I
2C-P (7524)................................  I
2C-T-4 (7532)..............................  I
AM-694 (7694)..............................  I
Phenylacetone (8501).......................  I
------------------------------------------------------------------------

    The company plans to manufacture the listed controlled substances 
for distribution to their research and forensic customers conducting 
drug testing and analysis.
    No comments or objections have been received. DEA has considered 
the factors in 21 U.S.C. 823(a) and determined that the registration of 
Cayman Chemical Company to manufacture the listed basic classes of 
controlled substances is consistent with the public interest at this 
time. DEA has investigated Cayman Chemical Company to ensure that the 
company's registration is consistent with the public interest. The 
investigation has included inspection and testing of the company's 
physical security systems, verification of the company's compliance 
with state and local laws, and a review of the company's background and 
history.
    Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 
CFR 1301.33, the above named company is granted registration as a bulk 
manufacturer of the basic classes of controlled substances listed.

     Dated: April 16, 2013.
 Joseph T. Rannazzisi,
 Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 2013-09530 Filed 4-22-13; 8:45 am]
BILLING CODE 4410-09-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.